Literature DB >> 32330795

The formulae and biologically active ingredients of Chinese herbal medicines for the treatment of atopic dermatitis.

Fenggen Yan1, Fei Li1, Junfeng Liu1, Siqi Ye1, Yu Zhang1, Jinjing Jia1, Hongyi Li1, Dacan Chen2, Xiumei Mo3.   

Abstract

Atopic dermatitis (AD) is a common relapsing inflammatory skin disease characterized by severe pruritus that seriously affects the quality of patients' life. There is an increasingly large amount of research demonstrating that traditional Chinese medicine (TCM) including herbal formulae and bioactive ingredients exerts pharmacological effects on atopic dermatitis. It has been a long history of TCM being used to treat atopic dermatitis, especially in preventing disease recurrence, maintaining long-term remission, and reducing disease burden. Nowadays, both of TCM monomer preparations and traditional formulae are still widely used. This review focuses on TCM as well as its bioactive ingredients for the treatment of AD, from the perspectives of animal model construction, pharmacodynamic mechanisms and clinical studies of formulae. To be more specific, the regulation and molecular mechanisms of the herbal formulae and bioactive ingredients of TCM are investigated, and the latest clinical research on TCM formulae is discussed. Furthermore, it provides a summary of the strengths and utilities of TCM, and will be useful for doctors who use Chinese medicine for treatment or researchers who select candidates for clinical treatments or further high-quality clinical studies.
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Active ingredients; Atopic dermatitis; Chinese herbal medicine; Formula; Treatment

Year:  2020        PMID: 32330795     DOI: 10.1016/j.biopha.2020.110142

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

1.  Inhibitory effects of isoliquiritin on an atopic dermatitis model through the CD177/JAK2/STAT pathway in vitro and in vivo.

Authors:  Qing Wu; Xiumei Mo; Ying Lin; Junfeng Liu; Siqi Ye; Yu Zhang; Xingxing Fan; Dacan Chen; Fenggen Yan
Journal:  Ann Transl Med       Date:  2022-09

2.  IL-32 promotes the occurrence of atopic dermatitis by activating the JAK1/microRNA-155 axis.

Authors:  Jing Chang; Bin Zhou; Zhu Wei; Yongqi Luo
Journal:  J Transl Med       Date:  2022-05-11       Impact factor: 8.440

3.  The efficacy and safety of Longmu Tang granule for the treatment of atopic dermatitis: study protocol for a single-centred, double-blinded, randomised, placebo-controlled trial.

Authors:  Ya-Qin Li; Tao-Tao Shen; Qing-Ying Wang; Meng-Xi Ma; Feng-Yan Tian; Yuan-Yao She; Yi-Cheng Tao; Jing-Jing Wang; Hui-Yan Chi; Na Lang; Jian-Xun Ren
Journal:  Trials       Date:  2022-05-09       Impact factor: 2.728

4.  Saikosaponin A and Saikosaponin C Reduce TNF-α-Induced TSLP Expression through Inhibition of MAPK-Mediated EGR1 Expression in HaCaT Keratinocytes.

Authors:  Sung Shin Ahn; Young Han Lee; Hyunjin Yeo; Euitaek Jung; Yoongho Lim; Soon Young Shin
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

5.  A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study.

Authors:  Zhen-Zhen Wang; Kun Li; Anish R Maskey; Weihua Huang; Anton A Toutov; Nan Yang; Kamal Srivastava; Jan Geliebter; Raj Tiwari; Mingsan Miao; Xiu-Min Li
Journal:  FASEB J       Date:  2021-04       Impact factor: 5.191

6.  Gentiana straminea supplementation improves feed intake, nitrogen and energy utilization, and methane emission of Simmental calves in northwest China.

Authors:  K L Xie; Z F Wang; Y R Guo; C Zhang; W H Zhu; F J Hou
Journal:  Anim Biosci       Date:  2021-10-29

7.  Efficacy and safety of Chinese herbal medicine for atopic dermatitis: Evidence from eight high-quality randomized placebo-controlled trials.

Authors:  Xiaoce Cai; Xiaoying Sun; Liu Liu; Yaqiong Zhou; Seokgyeong Hong; Jiao Wang; Jiale Chen; Miao Zhang; Chunxiao Wang; Naixuan Lin; Su Li; Rong Xu; Xin Li
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.